feed,title,long_url,short_url
Benzinga,"Protagonist To Go Ahead With Oral Peptide PN-235, Discontinues Phase 1 Candidate",https://benzinga.com/general/biotech/21/12/24428036/protagonist-to-go-ahead-with-oral-peptide-pn-235-discontinues-phase-1-candidate,https://j.mp/3omDEeF
Benzinga,Is It Time To Buy DocuSign Stock Following Q3 Results? Stephanie Link Weighs In,https://benzinga.com/news/earnings/21/12/24428888/is-it-time-to-buy-docusign-stock-following-q3-results-stephanie-link-weighs-in,https://j.mp/3pngh3U
Benzinga,BeiGene - EUSA Pharma's Siltuximab Approved In China For Multicentric Castleman Disease,https://benzinga.com/general/biotech/21/12/24428485/beigene-eusa-pharmas-siltuximab-approved-in-china-for-multicentric-castleman-disease,https://j.mp/31nd3VS
